PCV118 - FACTORS DETERMINING SELECTION OF APPROPRIATE PATIENTS FOR PCSK9 INHIBITORS IN EUROPEAN CLINICAL PRACTICE

Autor: B. Coll Crespo, H. Wieffer, M. Tai, Y. Qian, C. Cerezo Olmos, J. McKendrick

Publikováno v: Value in Health. 21:S112

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd42e9c77d6ea8e6235f1ff591395a3e
https://doi.org/10.1016/j.jval.2018.09.663

Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.

Autor: Baum SJ; Department of Integrated Medical Sciences, Charles E Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA.; Preventive Cardiology Inc, Boca Raton, FL, USA., Wade RL; Medical and Scientific Services, IQVIA, Plymouth Meeting, PA, USA., Xiang P; Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA., Arellano J; Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA., Cerezo Olmos C; US Medical, Amgen Inc, Thousand Oaks, CA, USA., Nunna S; Real-World Evidence Solutions, IQVIA, Plymouth Meeting, PA, USA., Chen CC; Real-World Evidence Solutions, IQVIA, Plymouth Meeting, PA, USA., Carter CM; Global Publications, Amgen Inc, Thousand Oaks, CA, USA., Desai NR; Section of Cardiovascular Medicine, Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, CT, USA.

Publikováno v: Therapeutics and clinical risk management [Ther Clin Risk Manag] 2019 Nov 13; Vol. 15, pp. 1325-1332. Date of Electronic Publication: 2019 Nov 13 (Print Publication: 2019).